Preclinical Assessment of the Receptor-binding Domain of Plasmodium Vivax Duffy-binding Protein As a Vaccine Candidate in Rhesus Macaques

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2008 Jun 25

PMID 18573299

Citations 19

Authors

A Moreno

I Caro-Aguilar

S S Yazdani

A R Shakri

S Lapp

E Strobert

H McClure

C E Chitnis

M R Galinski

Affiliations

Soon will be listed here.

Abstract

The receptor-binding domain of Plasmodium vivax Duffy-binding protein, region II (PvRII), is an attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and immunogenicity of recombinant PvRII in Macaca mulatta (rhesus monkeys). Recombinant PvRII with a C-terminal 6-histidine tag was expressed in E. coli, recovered from inclusion bodies, refolded into its functional conformation, purified to homogeneity and formulated with three adjuvants, namely, Alhydrogel, Montanide ISA 720 and the GSK proprietary Adjuvant System AS02A for use in immunogenicity studies. All the PvRII vaccine formulations tested were safe and highly immunogenic. The overall magnitude of the antibody response was significantly higher for both Montanide ISA 720 and AS02A formulations in comparison with Alhydrogel. Furthermore, there was a significant correlation between antibody recognition titers by ELISA and binding inhibition titers in in vitro binding assays. The PvRII vaccine formulations also induced IFN-gamma recall responses that were identified using ex vivo ELISPOT assays. These results provide support for further clinical development of a vaccine for P. vivax malaria based on recombinant PvRII.

Citing Articles

Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of in murine model.

da Silva Matos A, Soares I, Rodrigues-da-Silva R, Rodolphi C, Albrecht L, Donassolo R Front Immunol. 2024; 15:1392043.

PMID: 38962015 PMC: 11219565. DOI: 10.3389/fimmu.2024.1392043.

Structural basis for DARC binding in reticulocyte invasion by Plasmodium vivax.

Moskovitz R, Pholcharee T, DonVito S, Guloglu B, Lowe E, Mohring F Nat Commun. 2023; 14(1):3637.

PMID: 37336887 PMC: 10279640. DOI: 10.1038/s41467-023-39357-w.

vaccine: What is the best way to go?.

Soares da Veiga G, Moriggi M, Vettorazzi J, Muller-Santos M, Albrecht L Front Immunol. 2023; 13:910236.

PMID: 36726991 PMC: 9885200. DOI: 10.3389/fimmu.2022.910236.

Using Plasmodium knowlesi as a model for screening Plasmodium vivax blood-stage malaria vaccine targets reveals new candidates.

Ndegwa D, Kundu P, Hostetler J, Marin-Menendez A, Sanderson T, Mwikali K PLoS Pathog. 2021; 17(7):e1008864.

PMID: 34197567 PMC: 8279373. DOI: 10.1371/journal.ppat.1008864.

Progress towards the development of a vaccine.

De S, Ntumngia F, Nicholas J, Adams J Expert Rev Vaccines. 2021; 20(2):97-112.

PMID: 33481638 PMC: 7994195. DOI: 10.1080/14760584.2021.1880898.

References

MILLER L, Mason S, DVORAK J, McGinniss M, Rothman I . Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science. 1975; 189(4202):561-3. DOI: 10.1126/science.1145213. View

Flanagan K, Lee E, Gravenor M, Reece W, Urban B, Doherty T . Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J Immunol. 2001; 167(8):4729-37. DOI: 10.4049/jimmunol.167.8.4729. View

Michon P, Arevalo-Herrera M, Fraser T, Herrera S, Adams J . Serologic responses to recombinant Plasmodium vivax Duffy binding protein in a Colombian village. Am J Trop Med Hyg. 1998; 59(4):597-9. DOI: 10.4269/ajtmh.1998.59.597. View

Wertheimer S, Barnwell J . Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein. Exp Parasitol. 1989; 69(4):340-50. DOI: 10.1016/0014-4894(89)90083-0. View

Fraser T, Michon P, Barnwell J, Noe A, Kaslow D, Adams J . Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect Immun. 1997; 65(7):2772-7. PMC: 175391. DOI: 10.1128/iai.65.7.2772-2777.1997. View

Stewart V, Mcgrath S, Walsh D, Davis S, Hess A, Ware L . Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine. 2006; 24(42-43):6483-92. DOI: 10.1016/j.vaccine.2006.06.033. View

Dutta S, Daugherty J, Ware L, Lanar D, Ockenhouse C . Expression, purification and characterization of a functional region of the Plasmodium vivax Duffy binding protein. Mol Biochem Parasitol. 2000; 109(2):179-84. DOI: 10.1016/s0166-6851(00)00244-9. View

Jennes W, Kestens L, Nixon D, Shacklett B . Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15--the Amplispot assay. J Immunol Methods. 2002; 270(1):99-108. DOI: 10.1016/s0022-1759(02)00275-2. View

Grimberg B, Udomsangpetch R, Xainli J, McHenry A, Panichakul T, Sattabongkot J . Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med. 2007; 4(12):e337. PMC: 2140086. DOI: 10.1371/journal.pmed.0040337. View

10.

Bejon P, Kai O, Mwacharo J, Keating S, Lang T, Gilbert S . Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. Eur J Immunol. 2006; 36(8):2264-72. DOI: 10.1002/eji.200636187. View

11.

Choe H, Moore M, Owens C, Wright P, Vasilieva N, Li W . Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol. 2005; 55(5):1413-22. DOI: 10.1111/j.1365-2958.2004.04478.x. View

12.

Tran T, Oliveira-Ferreira J, Moreno A, Santos F, Yazdani S, Chitnis C . Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Am J Trop Med Hyg. 2005; 73(2):244-55. View

13.

Chitnis C, MILLER L . Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med. 1994; 180(2):497-506. PMC: 2191600. DOI: 10.1084/jem.180.2.497. View

14.

Pandey K, Singh S, Pattnaik P, Pillai C, Pillai U, Lynn A . Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol Biochem Parasitol. 2002; 123(1):23-33. DOI: 10.1016/s0166-6851(02)00122-6. View

15.

Cole-Tobian J, Cortes A, Baisor M, Kastens W, Xainli J, Bockarie M . Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis. 2002; 186(4):531-9. DOI: 10.1086/341776. View

16.

Xainli J, Baisor M, Kastens W, Bockarie M, Adams J, King C . Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J Immunol. 2002; 169(6):3200-7. DOI: 10.4049/jimmunol.169.6.3200. View

17.

Yazdani S, Shakri A, Chitnis C . A high cell density fermentation strategy to produce recombinant malarial antigen in E. coli. Biotechnol Lett. 2005; 26(24):1891-5. DOI: 10.1007/s10529-004-6040-4. View

18.

Collins W . South American monkeys in the development and testing of malarial vaccines--a review. Mem Inst Oswaldo Cruz. 1992; 87 Suppl 3:401-6. DOI: 10.1590/s0074-02761992000700068. View

19.

Guinovart C, Navia M, Tanner M, Alonso P . Malaria: burden of disease. Curr Mol Med. 2006; 6(2):137-40. DOI: 10.2174/156652406776055131. View

20.

Gibbs R, Rogers J, Katze M, Bumgarner R, Weinstock G, Mardis E . Evolutionary and biomedical insights from the rhesus macaque genome. Science. 2007; 316(5822):222-34. DOI: 10.1126/science.1139247. View